Breaking Down Biosimilars

New biosimilars are coming to market and there is a lot of confusion among patients about what this will mean for their treatment plan. We called on patient advocates Cristina Montoya and Lene Anders…

Through conversations with patient advocates Cristina Montoya and Lene Andersen, we learn that many of the emotions and discussions around starting (and staying on) a treatment are in fact the same f…

Many patients have questions and may be reluctant to make the switch to biosimilars at first. In this episode, hosts Zoe Rothblatt and Conner Mertens talk to a few patients about their experiences st…

Biosimilar medications must still win approval by the U.S. Food and Drug Administration. In this episode, co-hosts Zoe Rothblatt and Conner Mertens explore that approval process, and explain the uniq…

In this episode, Zoe and Conner check in with several patients who’ve made the switch to a biosimilar to find out how they’re doing. Some patients taking a biosimilar have to travel to an infusion si…

When biosimilars were introduced into the US, there was much talk about how much money they could potentially save patients. Getting a biosimilar developed and approved by the US Food & Drug Administ…

Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar…

The introduction of biosimilars in the US has been hampered by unrealized cost savings, myths and misinformation, and patient hesitancy. Still, many medical professionals see much to be optimistic ab…

Biosimilar medications were introduced into the US market in 2015, but they’re still relatively unfamiliar to many people. In our first episode, co-hosts Zoe Rothblatt and Conner Mertens provide an o…